What is it about?
To compare the efficacy of sustained-release (SR) bupropion to placebo in treating hypoactive sexual desire disorder (HSDD) in ovulating women.
Featured Image
Photo by JOSHUA COLEMAN on Unsplash
Why is it important?
Bupropion sustained release (SR) is effective in treating all the major categories of SSRI-induced sexual sideeffects. In addition, prosexual effects of bupropion have been reported in several studies. The beneficial effects of bupropion on HSDD in premenopausal women have also been reported [18]. Thus we conducted a double-blind placebo-controlled randomized study to address the effects of bupropion on HSDD in ovulating women.
Perspectives
The results of this controlled clinical trial show that bupropion SR significantly improved HSDD in ovulating women, as measured by several endpoints. Bupropion was relatively well tolerated with predictable adverse effects. Further studies are warranted to better elucidate the role of dopaminergic system in female sexual functioning and to replicate our results.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women, BJU International, August 2010, Wiley,
DOI: 10.1111/j.1464-410x.2010.09208.x.
You can read the full text:
Resources
Contributors
The following have contributed to this page
